Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). Biomarkers offer a potential prognostic or diagnostic indicator for disease manifestation, progression or both. Serum biomarkers, including total cholesterol, triglycerides, insulin resistance and C-peptide, have been used for many years. Emerging biomarkers, such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin and tumour necrosis factor-alpha, have been proposed as tools that could provide valuable complementary information to that obtained from traditional biomarkers. Moreover, markers of cell death and mitochondrial dysfunction (cytokeratins) represent powerful predictors of risk. For biomarkers to be clinically useful in accurately diagnosing and treating disorders, age-specific reference intervals that account for differences in sex and ethnic origin are a necessity.
The global non-alcoholic steatohepatitis biomarkers market segmentation is based on biomarker type (apoptosis biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, serum biomarkers) and end user (academics and research institute, diagnostic laboratories, pharma and CROs, and hospitals).
The global non-alcoholic steatohepatitis biomarkers market report provides market size (Revenue US$ Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global non-alcoholic steatohepatitis biomarkers market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global non-alcoholic steatohepatitis biomarkers market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global non-alcoholic steatohepatitis biomarkers market and included in this report are BioPredictive S.A.S, Exalenz Biosciences Ltd., Genfit SA, One Way Liver S.L., Prometheus Laboratories Inc. (Nestle Health Sciences), Quest Diagnostics Incorporated, Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics), and Siemens Healthcare Private Ltd. (Siemens Healthineers).